CN116445352A - 一种副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01及其在制备具有抗氧化或抗衰老作用的产品中的应用 - Google Patents
一种副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01及其在制备具有抗氧化或抗衰老作用的产品中的应用 Download PDFInfo
- Publication number
- CN116445352A CN116445352A CN202310456134.3A CN202310456134A CN116445352A CN 116445352 A CN116445352 A CN 116445352A CN 202310456134 A CN202310456134 A CN 202310456134A CN 116445352 A CN116445352 A CN 116445352A
- Authority
- CN
- China
- Prior art keywords
- paracasei
- lactobacillus paracasei
- hclp01
- lacticaseibacillus
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 141
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 29
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 29
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 88
- 239000000203 mixture Substances 0.000 claims abstract description 56
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 44
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 44
- 239000004220 glutamic acid Substances 0.000 claims abstract description 44
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 44
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 43
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 43
- 239000003814 drug Substances 0.000 claims abstract 2
- 239000000843 powder Substances 0.000 claims description 53
- 239000008176 lyophilized powder Substances 0.000 claims description 38
- 239000000047 product Substances 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 12
- 230000032683 aging Effects 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 41
- 229960002989 glutamic acid Drugs 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 26
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 23
- 229940118019 malondialdehyde Drugs 0.000 description 23
- 102000019197 Superoxide Dismutase Human genes 0.000 description 22
- 108010012715 Superoxide dismutase Proteins 0.000 description 22
- 241000244203 Caenorhabditis elegans Species 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 13
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 12
- 241000244206 Nematoda Species 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 229940099596 manganese sulfate Drugs 0.000 description 3
- 239000011702 manganese sulphate Substances 0.000 description 3
- 235000007079 manganese sulphate Nutrition 0.000 description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- KXLBZYRJOGUGLR-UHFFFAOYSA-N 2,2-bis(prop-2-enoyloxymethyl)butyl prop-2-enoate prop-2-enoic acid Chemical compound OC(=O)C=C.CCC(COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C KXLBZYRJOGUGLR-UHFFFAOYSA-N 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000005184 irreversible process Methods 0.000 description 1
- 230000035777 life prolongation Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及医学技术领域,具体公开了一种副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01及其在制备具有抗氧化或抗衰老作用的产品中的应用。所述的副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01,其保藏编号为GDMCC No:63142。所述的组合物,其包含副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01、γ‑氨基丁酸以及谷氨酸。研究表明,本发明所述的副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01具有抗氧化以及抗衰老作用;并且其抗氧化以及抗衰老作用要优于或显著优于已知的副干酪乳杆菌。
Description
技术领域
本发明涉及生物医学技术领域,具体涉及一种副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01及其在制备具有抗氧化或抗衰老作用的产品中的应用。
背景技术
衰老是生物发育成熟、年龄增大之后的自身机能减退,机体内环境稳定性以及应激能力下降、机能逐步退行性改变的不可逆过程。氧化以及炎症性衰老、免疫衰老以及肠道菌群失调等均是诱发机体衰老的因素。大量研究发现,定殖在人体内,能够改变宿主某一部位菌群组成的益生菌及其分泌的短链脂肪酸等具有抗衰老活性,并主要体现在对肠道微生物群的积极调节、免疫调节以及寿命延长方面。
然而,现有的可以产品化应用的具有抗衰老作用的益生菌种类有限;继续开发更多的具有抗衰老作用的益生菌具有重要的应用价值。
发明内容
为了克服现有技术中存在的至少之一的技术问题,本发明首先提供了一种副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01。
本发明提供的副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01,其保藏编号为GDMCC No:63142。
该菌株已于2023年1月13日保藏于广东省微生物菌种保藏中心(地址是广州市先烈中路100号大院59号楼5楼广东省科学院微生物研究所)。
所述的副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01形态为短杆状,经分析其16s rRNA序列(如SEQ ID NO:1所示),利用测序结果在NCBI数据库中进行比对,与GenBank中副干酪乳杆菌(Lacticaseibacillus paracasei)的同源性为99.93%。
发明人在大量的实验中筛选得到了一种全新的副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01,发明人在进一步研究中惊奇的发现,其具有抗氧化以及抗衰老作用;并且其抗氧化以及抗衰老作用要优于,甚至显著优于已知的副干酪乳杆菌。
本发明还提供了一种组合物,其包含副干酪乳杆菌(Lacticaseibacillusparacasei)HCLP01、γ-氨基丁酸以及谷氨酸。
发明人在进一步研究中惊奇的发现,将副干酪乳杆菌(Lacticaseibacillusparacasei)HCLP01与γ-氨基丁酸以及谷氨酸组合后得到的组合物,其抗氧化以及抗衰老作用进一步显著高于单独的副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01;同时其抗氧化以及抗衰老作用也进一步显著高于单独的γ-氨基丁酸或单独的谷氨酸;具有更加显著的抗氧化以及抗衰老作用;这可能是由于将副干酪乳杆菌(Lacticaseibacillusparacasei)HCLP01、γ-氨基丁酸以及谷氨酸三者混合后产生协同增效的结果。
优选地,所述的副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01为副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01冻干粉。
进一步优选地,副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01冻干粉、γ-氨基丁酸以及谷氨酸的质量比为1:(0.01-1):(1-100)。
更进一步优选地,副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01冻干粉、γ-氨基丁酸以及谷氨酸的质量比为1:(0.5-0.8):(1-50)。
最优选地,副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01冻干粉、γ-氨基丁酸以及谷氨酸的质量比为1:0.75:12.5。
本发明还提供了一种上述副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01在制备具有抗氧化或抗衰老作用的产品中的应用。
本发明还提供了一种上述组合物在制备具有抗氧化或抗衰老作用的产品中的应用。
优选地,所述的产品为食品、膳食补充剂、功能性食品、保健品或药物。
优选地,所述产品的剂型为丸剂、胶囊剂、片剂、颗粒剂或粉剂。
有益效果:本发明首先提供了一种全新的副干酪乳杆菌(Lacticaseibacillusparacasei)HCLP01;研究表明,其具有抗氧化以及抗衰老作用;并且其抗氧化以及抗衰老作用要优于或显著优于已知的副干酪乳杆菌。发明人在进一步研究中发现,将副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01与γ-氨基丁酸以及谷氨酸组合后得到的组合物,其抗氧化以及抗衰老作用进一步显著高于单独的副干酪乳杆菌(Lacticaseibacillusparacasei)HCLP01;同时其抗氧化以及抗衰老作用也进一步显著高于单独的γ-氨基丁酸或单独的谷氨酸;具有更加显著的抗氧化以及抗衰老作用。
由于所述的副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01以及组合物具有抗氧化以及抗衰老作用;因此,将本发明所述的副干酪乳杆菌(Lacticaseibacillusparacasei)HCLP01或组合物作为有效成分用于制备具有抗氧化或抗衰老作用的产品具有重要的应用价值。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例的附图,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为副干酪乳杆菌HCLP01、γ-氨基丁酸、谷氨酸以及组合物对小鼠血清GSH-Px、T-AOC、SOD及MDA含量的影响
图2为副干酪乳杆菌HCLP01、γ-氨基丁酸、谷氨酸以及组合物对小鼠肝脏GSH-Px、T-AOC、SOD及MDA含量的影响
图3为副干酪乳杆菌HCLP01、γ-氨基丁酸、谷氨酸以及组合物对正常及氧化应激条件下秀丽隐杆线虫平均寿命的影响
图4为副干酪乳杆菌HCLP01、γ-氨基丁酸、谷氨酸以及组合物对秀丽隐杆线虫SOD活性、ROS、MDA含量的影响。
具体实施方式
下面将结合实施例对本发明技术方案进行清楚、完整地描述。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01的分离与鉴定
(1)富集培养:取来自健康儿童的粪便处理液加入含有谷氨酸的培养基(蛋白胨10.0g/L,牛肉浸粉4.0g/L,酵母浸粉4.0g/L,葡萄糖20.0g/L,磷酸氢二钾2.0g/L,柠檬酸三铵2.0g/L,醋酸钠5.0g/L,硫酸镁0.2g/L,硫酸锰0.05g/L,吐温-80 1.0g/L)中,33℃静止培养6h。
(2)定性检测:分别对实施例1步骤(1)培养后的培养液进行浓缩、定性检测。薄层层析法,将经过浓缩处理的发酵液点样到硅胶预制板上,层析液展开。层析液采用氯仿:冰醋酸:水(60:25:15),添加0.5%的茚三酮。展开结束后自然晾干,90℃显色5min,与标样比较。
(3)分离单菌落:对实施例1步骤(2)获得的有γ-氨基丁酸生成的培养液,先进行镜检,判断细菌种类,进而稀释涂布,涂布平板培养基为含有10g/L CaCO3的益生菌固体培养基(蛋白胨10.0g/L,牛肉浸粉4.0g/L,酵母浸粉4.0g/L,葡萄糖20.0g/L,磷酸氢二钾2.0g/L,柠檬酸三铵2.0g/L,醋酸钠5.0g/L,硫酸镁0.2g/L,硫酸锰0.05g/L,吐温-80 1.0g/L,琼脂15.0g/L),33℃培养6h,挑取若干有溶钙圈(湿润光滑,边缘整齐,小圆)的菌落,接种至含谷氨酸的培养基中,33℃,静止6h,定性检测并比较γ-氨基丁酸产量大小;挑选出γ-氨基丁酸产量最高的菌株,即得所述的副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01(以下简写为副干酪乳杆菌HCLP01);
其中,副干酪乳杆菌HCLP01的菌体形态为短杆状,经分析其16s rRNA序列(如SEQID NO:1所示),利用测序结果在NCBI数据库中进行比对,与GenBank中副干酪乳杆菌(Lacticaseibacillus paracasei)的同源性为99.93%。
实施例2副干酪乳杆菌HCLP01冻干粉的制备
(1)副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01种子液制备:将HCLP01菌种接入培养基(培养基成分为:蛋白胨11.0g/L,酵母粉11.0g/L,葡萄糖11.0g/L,吐温80 1.2mL/L,乙酸钠6.0g/L,磷酸氢二钾2.5g/L,硫酸镁0.7g/L,硫酸锰0.5g/L,谷氨酸11.0g/L),摇瓶发酵12h,获得OD 600>1.0的副干酪乳杆菌(Lacticaseibacillusparacasei)HCLP01种子液。
(2)扩大培养:将步骤(1)所得的副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01种子液接入10L发酵罐中的液体培养基(10L,培养基成分为:蛋白胨11.0g/L,酵母粉11.0g/L,葡萄糖11.0g/L,吐温80 1.2mL/L,乙酸钠6.0g/L,磷酸氢二钾2.5g/L,硫酸镁0.7g/L,硫酸锰0.5g/L,谷氨酸11.0g/L);搅拌培养24h,结束发酵得发酵液;
(3)将步骤(2)所得发酵液离心收集菌体,然后添加水以及冻干保护剂脱脂乳粉混合均匀后经冷冻干燥后制得活菌数为10亿cfu/g的副干酪乳杆菌HCLP01冻干粉。
实施例3组合物的制备
将1.0g按实施例2方法制备得到的副干酪乳杆菌HCLP01冻干粉(活菌数为10亿cfu/g)和0.75gγ-氨基丁酸、12.5g谷氨酸混合均匀,即得所述的组合物。
效果实施例1小鼠抗氧化功能实验
测试样品为:按实施例2所述方法制备得到的副干酪乳杆菌HCLP01冻干粉(活菌数为10亿cfu/g)、γ-氨基丁酸、谷氨酸、按实施例3所述方法制备得到的组合物、副干酪乳杆菌IMC-4冻干粉(活菌数为100亿cfu/g)及副干酪乳杆菌LC-01冻干粉(活菌数为100亿cfu/g)。
取健康balb/c小鼠80只,饲养温度为20-22℃,自然光照,自由进食饮水,在此条件下用普通饲料喂养5d。将小白鼠随机分成8组,(正常对照组及模型对照组、副干酪乳杆菌HCLP01冻干粉组、γ-氨基丁酸组、谷氨酸组、组合物组、副干酪乳杆菌IMC-4冻干粉组及副干酪乳杆菌LC-01冻干粉组。除正常对照组外,其余各组腹部注射700mg/(kg·d)D-半乳糖建立氧化损伤模型,副干酪乳杆菌HCLP01冻干粉组、γ-氨基丁酸组、谷氨酸组、组合物组、副干酪乳杆菌IMC-4冻干粉组、副干酪乳杆菌LC-01冻干粉组按照10mg/(kg·d)的剂量灌胃,正常对照组注射等体积的生理盐水,灌胃等体积的蒸馏水,每2d称体质量1次,持续28d。实验结束后,眼球取血处死小鼠,参考ELISA试剂盒使用说明测定血清、肝脏中超氧化物歧化酶(SOD)活性、谷胱甘肽过氧化物酶(GSH-Px)活性、丙二醛(MDA)含量和总抗氧化能力(T-AOC)。
Control组:正常对照组;Model control组:(D-半乳糖)模型对照组;A组:副干酪乳杆菌HCLP01冻干粉组;B组:γ-氨基丁酸组;C组:谷氨酸组;D组:组合物组;E组:副干酪乳杆菌IMC-4冻干粉组;F组:副干酪乳杆菌LC-01冻干粉组。
实验结果:
由图1a、b、c、d可知,注射D-半乳糖后,小鼠血清GSH-Px、SOD、T-AOC活性与正常对照组相比显著下降,而小鼠血清MDA含量与正常对照组相比显著升高。相比于正常对照组,模型对照组小鼠血清GSH-Px、SOD、T-AOC活性分别降低22.5%(p<0.01)、34.1%(p<0.01)、51.9%(p<0.01),而模型对照组小鼠血清MDA含量升高86.3%(p<0.01)。说明,D-半乳糖暴露诱导小鼠氧化损伤,小鼠抗氧化能力降低。而经副干酪乳杆菌HCLP01冻干粉、γ-氨基丁酸、谷氨酸、组合物、副干酪乳杆菌IMC-4冻干粉及副干酪乳杆菌LC-01冻干粉灌胃治疗之后,与模型损伤组相比,小鼠血清GSH-Px、SOD、T-AOC活性明显恢复。其中,经副干酪乳杆菌HCLP01冻干粉及组合物灌胃之后,与模型损伤组相比,小鼠血清GSH-Px、SOD、T-AOC活性恢复最为显著。进一步分析实验结果发现,经副干酪乳杆菌HCLP01冻干粉、γ-氨基丁酸、谷氨酸、组合物、副干酪乳杆菌IMC-4冻干粉及副干酪乳杆菌LC-01冻干粉灌胃之后,与模型损伤组相比,小鼠血清MDA含量明显下降;类似的,副干酪乳杆菌HCLP01冻干粉及组合物对小鼠清除血清MDA的活性要显著强于γ-氨基丁酸、谷氨酸及副干酪乳杆菌IMC-4冻干粉以及副干酪乳杆菌LC-01冻干粉。进一步分析实验结果显示,组合物对小鼠清除血清MDA的活性及提高小鼠血清GSH-Px、SOD、T-AOC活性强于同等用量条件下的副干酪乳杆菌HCLP01冻干粉、γ-氨基丁酸及谷氨酸,我们推测可能是组合物中的副干酪乳杆菌HCLP01冻干粉、γ-氨基丁酸以及谷氨酸三者发挥协同作用,能够更好的提高小鼠的抗氧化、缓解衰老的活性,进而能够对小鼠血清中的抗氧化酶活性及MDA含量进行调控。
由图2a、b、c、d可知,注射D-半乳糖后,小鼠肝脏的GSH-Px、SOD、T-AOC活性与正常对照组相比显著降低,而小鼠肝脏中MDA含量与正常对照组相比显著增加。相比于正常对照组,模型对照组小鼠肝脏GSH-Px、SOD、T-AOC活性分别降低30.9%(p<0.01)、62.5%(p<0.01)、57.1%(p<0.01),而模型对照组小鼠肝脏MDA含量升高38.4%(p<0.01)。本部分实验数据进一步说明,D-半乳糖暴露使小鼠抗氧化能力降低,小鼠受到严重的氧化损伤。而经副干酪乳杆菌HCLP01冻干粉、γ-氨基丁酸、谷氨酸、组合物、副干酪乳杆菌IMC-4冻干粉及副干酪乳杆菌LC-01冻干粉灌胃治疗之后,与模型损伤组相比,小鼠肝脏GSH-Px、SOD、T-AOC活性得到明显恢复。其中,经副干酪乳杆菌HCLP01冻干粉及组合物灌胃之后,与模型损伤组相比,小鼠肝脏GSH-Px、SOD、T-AOC活性恢复最显著。进一步分析实验结果发现,经副干酪乳杆菌HCLP01冻干粉、γ-氨基丁酸、谷氨酸、组合物、副干酪乳杆菌IMC-4冻干粉及副干酪乳杆菌LC-01冻干粉灌胃治疗之后,与模型损伤组相比,小鼠肝脏MDA含量明显下降。其中,副干酪乳杆菌HCLP01冻干粉及组合物对小鼠清除肝脏MDA的活性显著强于同等剂量的γ-氨基丁酸、谷氨酸及副干酪乳杆菌IMC-4冻干粉以及副干酪乳杆菌LC-01冻干粉。进一步分析实验结果显示,组合物对小鼠清除肝脏MDA的活性及提高小鼠肝脏GSH-Px、SOD、T-AOC活性强于同等用量条件下的副干酪乳杆菌HCLP01冻干粉、γ-氨基丁酸及谷氨酸。我们认为,组合物中的副干酪乳杆菌HCLP01冻干粉、γ-氨基丁酸以及谷氨酸能够发挥协同作用以更好的提高小鼠肝脏抗氧化酶活性,进而提高小鼠的抗氧化能力。
综上所述,由上述结果可知:副干酪乳杆菌HCLP01其抗氧化作用要显著优于已知的副干酪乳杆菌IMC-4以及副干酪乳杆菌LC-01;同时,将副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01与γ-氨基丁酸以及谷氨酸组合后得到的组合物,其抗氧化作用得到了进一步的显著提高;其抗氧化作用要显著高于单独的副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01、γ-氨基丁酸或谷氨酸。
效果实施例2正常培养条件下秀丽隐杆线虫抗氧化、抗衰老实验
测试样品为:按实施例2所述方法制备得到的副干酪乳杆菌HCLP01冻干粉(活菌数为10亿cfu/g)、γ-氨基丁酸、谷氨酸、按实施例3所述方法制备得到的组合物、副干酪乳杆菌IMC-4冻干粉(活菌数为100亿cfu/g)及副干酪乳杆菌LC-01冻干粉(活菌数为100亿cfu/g)。
取N2野生型秀丽隐杆线虫于20℃条件下培养,并随机分成7组(每组数量不小于50条),每组3个平行对照组。实验组按照活性物10μg/mL的剂量预培养4天,正常对照组用磷酸缓冲盐溶液代替活性物,每天计数1次,直至所有虫体死亡。
Control组:正常对照组;A组:副干酪乳杆菌HCLP01冻干粉组;B组:γ-氨基丁酸组;C组:谷氨酸组;D组:组合物组;E组:副干酪乳杆菌IMC-4冻干粉组;F组:副干酪乳杆菌LC-01冻干粉组。
结果如图3a所示,除γ-氨基丁酸及谷氨酸外,副干酪乳杆菌HCLP01冻干粉、组合物、副干酪乳杆菌IMC-4冻干粉售副干酪乳杆菌LC-01冻干粉均能够提高N2野生型线虫的寿命。与正常对照组相比,副干酪乳杆菌HCLP01冻干粉、组合物、副干酪乳杆菌IMC-4冻干粉及副干酪乳杆菌LC-01冻干粉预处理后秀丽隐杆线虫平均寿命分别提高25.1%(p<0.01)、38.6%(p<0.01)、22.2%(p<0.01)、20.1%(p<0.01)。实验结果数据表明,相比于同等用量的副干酪乳杆菌HCLP01、γ-氨基丁酸及谷氨酸,组合物具有更优秀的提高秀丽隐杆线虫寿命的能力。同样的,相比于同等用量的副干酪乳杆菌HCLP01冻干粉、副干酪乳杆菌IMC-4冻干粉及售副干酪乳杆菌LC-01冻干粉,组合物具有更优秀的提高秀丽隐杆线虫寿命的能力。
效果实施例3氧化应激条件下秀丽隐杆线虫抗氧化、抗衰老实验
测试样品为:按实施例2所述方法制备得到的副干酪乳杆菌HCLP01冻干粉(活菌数为10亿cfu/g)、γ-氨基丁酸、谷氨酸、按实施例3所述方法制备得到的组合物、副干酪乳杆菌IMC-4冻干粉(活菌数为100亿cfu/g)及副干酪乳杆菌LC-01冻干粉(活菌数为100亿cfu/g)。
取N2野生型秀丽隐杆线虫于20℃条件下培养,并随机分成8组(每组数量不小于50条),每组3个平行对照组。正常对照组用磷酸缓冲盐溶液代替活性物,实验组按照活性物10μg/mL的剂量预培养4天,除正常对照组外,其余各组线虫转移至含有百草枯(10nM)的培养皿上继续培养4天后计数活体秀丽隐杆线虫数量并计算存活率。
Control组:正常对照组;Model control组:(百草枯)模型对照组;A组:副干酪乳杆菌HCLP01冻干粉组;B组:γ-氨基丁酸组;C组:谷氨酸组;D组:组合物组;E组:副干酪乳杆菌IMC-4冻干粉组;F组:副干酪乳杆菌LC-01冻干粉组。
结果如图3b所示,相比于正常对照组,百草枯处理后线虫的存活率显著降低。相比于正常对照组,百草枯处理组线虫寿命降低43.7%(p<0.01)。而经副干酪乳杆菌HCLP01冻干粉、组合物、副干酪乳杆菌IMC-4冻干粉及副干酪乳杆菌LC-01冻干粉预培养的线虫的存活率高于百草枯处理组。相比于百草枯处理组,副干酪乳杆菌HCLP01冻干粉、组合物、副干酪乳杆菌IMC-4冻干粉及副干酪乳杆菌LC-01组线虫的存活率分别提高27.2%(p<0.01)、36.1%(p<0.01)、21.4%(p<0.01)、19.0%(p<0.01)。与效果实施例2类似,副干酪乳杆菌HCLP01冻干粉、组合物、副干酪乳杆菌IMC-4冻干粉及副干酪乳杆菌LC-01冻干粉均能够显著提高N2野生型线虫的存活率。实验结果数据表明,相比于同等用量的副干酪乳杆菌HCLP01,组合物具有更优秀的提高秀丽隐杆线虫存活率的活性。副干酪乳杆菌HCLP01其对于高秀丽隐杆线虫存活率提高程度要显著高于副干酪乳杆菌IMC-4冻干粉及副干酪乳杆菌LC-01冻干粉。同样的,相比于同等用量的副干酪乳杆菌HCLP01冻干粉、副干酪乳杆菌IMC-4冻干粉及副干酪乳杆菌LC-01冻干粉,组合物具有更优秀的提高秀丽隐杆线虫存活率的活性。
取N2野生型秀丽隐杆线虫于20℃条件下培养,并随机分成8组(每组数量不小于50条),每组3个平行对照组。正常对照组用磷酸缓冲盐溶液代替活性物,实验组按照活性物10μg/mL的剂量预培养4天,除正常对照组外,其余各组线虫转移至含有百草枯(10nM)的培养皿上继续培养4天后。收集活体线虫,测定相同数量的活体线虫体内相关抗氧化酶活性(超氧化物歧化酶SOD)及活性氧(ROS)、丙二醛(MDA)含量。
结果如图4a、b、c所示,百草枯处理后,线虫抗氧化酶SOD活性与正常对照组相比显著下降,ROS、MDA含量与正常对照组相比显著升高,说明百草枯暴露显著诱导秀丽隐杆线虫氧化应激,使秀丽隐杆线虫受到严重的氧化损伤。相比于正常对照组,百草枯暴露组线虫抗氧化酶SOD活性降低38.5%(p<0.01),而ROS、MDA含量分别增加258.6%(p<0.01)、111.3%(p<0.01)。而经副干酪乳杆菌HCLP01冻干粉、组合物、副干酪乳杆菌IMC-4冻干粉及副干酪乳杆菌LC-01冻干粉预处理组的秀丽隐杆线虫抗氧化酶SOD活性高于百草枯处理组,且ROS、MDA含量低于百草枯处理组。进一步的分析实验结果发现组合物提高秀丽隐杆线虫抗氧化酶SOD活性及提高秀丽隐杆线虫清除ROS、MDA活性强于同等用量的副干酪乳杆菌HCLP01冻干粉、γ-氨基丁酸及谷氨酸。同时,组合物提高秀丽隐杆线虫抗氧化酶SOD活性及提高秀丽隐杆线虫清除ROS、MDA活性强于同等用量的副干酪乳杆菌IMC-4冻干粉及副干酪乳杆菌LC-01冻干粉。我们推测副干酪乳杆菌HCLP01冻干粉、γ-氨基丁酸及谷氨酸可能是通过发挥协同作用提高秀丽隐杆线虫抗氧化酶SOD活性及提高秀丽隐杆线虫清除ROS、MDA活性。
以上所揭露的仅为本发明较佳实施例而已,当然不能以此来限定本发明之权利范围,本领域普通技术人员可以理解实现上述实施例的全部或部分流程,并依本发明权利要求所作的等同变化,仍属于发明所涵盖的范围。
综上所述,由上述结果可知:副干酪乳杆菌HCLP01其抗衰老作用要优于已知的副干酪乳杆菌IMC-4以及副干酪乳杆菌LC-01;同时,将副干酪乳杆菌(Lacticaseibacillusparacasei)HCLP01与γ-氨基丁酸以及谷氨酸组合后得到的组合物,其抗衰老作用得到了进一步的显著提高;其抗衰老作用要显著高于单独的副干酪乳杆菌(Lacticaseibacillusparacasei)HCLP01、γ-氨基丁酸或谷氨酸。
Claims (10)
1.一种副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01,其保藏编号为GDMCCNo:63142。
2.一种组合物,其特征在于,包含副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01、γ-氨基丁酸以及谷氨酸。
3.根据权利要求2所述的组合物,其特征在于,所述的副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01为副干酪乳杆菌(Lacticaseibacillusparacasei)HCLP01冻干粉。
4.根据权利要求3所述的组合物,其特征在于,副干酪乳杆菌(Lacticaseibacillusparacasei)HCLP01冻干粉、γ-氨基丁酸以及谷氨酸的质量比为1:(0.01-1):(1-100)。
5.根据权利要求3所述的组合物,其特征在于,副干酪乳杆菌(Lacticaseibacillusparacasei)HCLP01冻干粉、γ-氨基丁酸以及谷氨酸的质量比为1:(0.5-0.8):(1-50)。
6.根据权利要求3所述的组合物,其特征在于,副干酪乳杆菌(Lacticaseibacillusparacasei)HCLP01冻干粉、γ-氨基丁酸以及谷氨酸的质量比为1:0.75:12.5。
7.权利要求1所述的副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01在制备具有抗氧化或抗衰老作用的产品中的应用。
8.权利要求2~6任一项所述的组合物在制备具有抗氧化或抗衰老作用的产品中的应用。
9.根据权利要求7或8所述的应用,其特征在于,产品为食品、膳食补充剂、功能性食品、保健品或药物。
10.根据权利要求7或8所述的应用,其特征在于,所述产品的剂型为丸剂、胶囊剂、片剂、颗粒剂或粉剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310456134.3A CN116445352A (zh) | 2023-04-18 | 2023-04-18 | 一种副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01及其在制备具有抗氧化或抗衰老作用的产品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310456134.3A CN116445352A (zh) | 2023-04-18 | 2023-04-18 | 一种副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01及其在制备具有抗氧化或抗衰老作用的产品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116445352A true CN116445352A (zh) | 2023-07-18 |
Family
ID=87135558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310456134.3A Pending CN116445352A (zh) | 2023-04-18 | 2023-04-18 | 一种副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01及其在制备具有抗氧化或抗衰老作用的产品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116445352A (zh) |
-
2023
- 2023-04-18 CN CN202310456134.3A patent/CN116445352A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110835616B (zh) | 副干酪乳杆菌gks6的活性物质、含其的组合物及其促进长寿的用途 | |
JP4022776B2 (ja) | コレステロールを低下および同化する能力を有する酸および胆汁酸塩耐性のLactobacillus分離株 | |
CN108384735B (zh) | 植物乳杆菌ccfm1019、其发酵食品及其在制备药物中的应用 | |
CN108076643B (zh) | 用于治疗例如细菌性阴道病的鼠李糖乳杆菌细菌 | |
JP2008507991A (ja) | 体脂肪低下機能性ラクトバシラスラムノサスとこれを含有した食品{lactobacillusrhamnosuswithbody‐fatreducingactivityandfoodscontainingthem} | |
CN110833565B (zh) | 植物乳杆菌gkm3的活性物质、含其的组合物及其促进长寿的用途 | |
CN116555076B (zh) | 一株长双歧杆菌长亚种my1及其在制备通便和护肠食品药品中的应用 | |
CN108570428B (zh) | 乳酸乳球菌乳酸亚种ccfm1018、其发酵食品及其在制备药物中的应用 | |
CN114561320B (zh) | 乳酸杆菌益生菌CGMCC No.1.13855在制备肝病治疗药物中的应用 | |
CN110835615B (zh) | 乳双歧杆菌gkk2的活性物质、含其的组合物及其促进长寿的用途 | |
WO2011102035A1 (ja) | 疾患の予防改善剤、持久力向上剤、抗疲労剤、並びにそれらを用いた医薬品および飲食品 | |
CN116555075B (zh) | 一株植物乳植杆菌jf1及其在制备抗衰老食品药品中的应用 | |
CN110684682B (zh) | 缓解pfoa毒害作用的多功能干酪乳杆菌ccfm1052、其发酵食品及应用 | |
CN117004503B (zh) | 一株唾液联合乳杆菌mb1及其在制备助睡眠和调理肠胃食品药品中的应用 | |
EP1424075B1 (en) | Acid and bile-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol | |
CN114533768B (zh) | 乳酸杆菌益生菌CGMCC No.1.13855在制备糖尿病治疗药物中的应用 | |
CN116445352A (zh) | 一种副干酪乳杆菌(Lacticaseibacillus paracasei)HCLP01及其在制备具有抗氧化或抗衰老作用的产品中的应用 | |
CN116656526B (zh) | 一株植物乳植杆菌jf4及其在制备降血糖和降胆固醇食品药品中的应用 | |
CN116286519B (zh) | 一株副干酪乳酪杆菌ks3及其在制备抗衰老和助消化食品药品中的应用 | |
CN116355812A (zh) | 罗伊氏乳杆菌(Limosilactobacillus reuteri)HCLR01及其在制备具有抗衰老作用的产品中的应用 | |
CN117286057A (zh) | 一种长双歧杆菌长亚种(Bifidobacterium longum)HEPRO-261及其应用 | |
CN117987482A (zh) | 一株粪肠球菌xy7及其在制备抗衰老和助睡眠食品药品中的应用 | |
CN118109345A (zh) | 一株粪肠球菌xy3及其在制备抗炎和助睡眠食品药品中的应用 | |
CN116987645A (zh) | 一种植物乳植杆菌(Lactiplantibacillus plantarum)HEPRO-185及其应用 | |
CN115960784A (zh) | 一种植物乳杆菌zjuf sys1及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |